Holostem Terapie Avanzate begins its transition to a Foundation
The board of directors unanimously approved the company’s evolution into a nonprofit organization
Holostem will remain an international point of reference for patients and research
Modena, 1st of June 2022 – The Board of Directors of Holostem Terapie Avanzate, which met on May 25, 2022 under the chairmanship of Andrea Chiesi, unanimously approved the begin of the transformation path from a company to a foundation. The decision marks the start of a new phase for Holostem, fourteen years after its opening. The process that will lead the new Foundation to be a nonprofit organization will be realized in the next months thanks to a new governance and a renewed shareholder commitment.
The excellence of Holostem Terapie Avanzate, the first biotechnology company in Italy dedicated to the development, manufacture, registration and distribution of Advanced Therapy Medicinal Products (ATMPs) based on cultures of epithelial stem cell for cell and gene therapy, will continue to be a point of reference in the national and international scientific landscape by continuing with its mission and values.
“This new challenge will allow us to highlight even more the ethical role that has always characterized our organization alongside scientific excellence. We wanted to give Holostem a new face in order to achieve new goals for the benefit of patients and research,” Holostem President Andrea Chiesi declared.
As announced during the Board meeting, Antonio Irione has been appointed CEO to lead Holostem in this transition phase: Antonio has 30 years of experience in pharmaceutical/healthcare and a solid specialization in business transformation.
“In line with the new direction, starting today, Antonio will succeed as CEO to Marco Dieci, whom we thank for his valuable work over the years at the helm of the company,” Andrea Chiesi concluded.
- Newcastle pharmacy experts work with Italian biotech lab to provide access to sight-saving treatment across England
- Holostem Terapie Avanzate begins its transition to a Foundation
- Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
- Gene therapy for butterfly children: 5-year follow-up published in the New England Journal of Medicine
- Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa